See more : Williams Industrial Services Group Inc. (WLMSQ) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Medicine (MindMed) Inc. (MNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Oranco, Inc. (ORNC) Income Statement Analysis – Financial Results
- Anima Holding S.A. (ANIM3.SA) Income Statement Analysis – Financial Results
- Killam Apartment REIT (KMP-UN.TO) Income Statement Analysis – Financial Results
- Woluwe Extension SA (WOLE.BR) Income Statement Analysis – Financial Results
- Bukit Jalil Global Acquisition 1 Ltd (BUJAW) Income Statement Analysis – Financial Results
Mind Medicine (MindMed) Inc. (MNMD)
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.16M | 3.22M | 2.62M | 0.00 | 6.68K | 6.68K | 5.50K | 0.00 | 0.00 |
| Gross Profit | -3.16M | -3.22M | -2.62M | 0.00 | -6.68K | -6.68K | -5.50K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.96M | 36.17M | 34.79M | 18.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 41.74M | 30.16M | 59.07M | 14.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.74M | 30.16M | 59.07M | 14.40M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Other Expenses | 0.00 | 2.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Cost & Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 468.18K | 861.94K | 1.24M | 111.25K | 94.55K |
| Interest Income | 4.66M | 1.50M | 0.00 | 0.00 | 0.00 | 4.00K | 8.40K | 1.20K | 1.90K |
| Interest Expense | 0.00 | 1.50M | 359.00K | 164.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.16M | 3.22M | 2.62M | 206.30K | 6.68K | 6.68K | 5.50K | 0.00 | 0.39 |
| EBITDA | -92.57M | -53.57M | -91.22M | -33.77M | -1.11M | -851.26K | -1.51M | -111.25K | -92.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.87M | -66.33M | -96.36M | -33.03M | -468.18K | -861.94K | -1.24M | -111.25K | -94.55K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.87M | 9.54M | -339.00K | -907.00K | -647.63K | 4.00K | 8.40K | -68.65K | 1.89K |
| Income Before Tax | -95.73M | -56.80M | -94.19M | -33.94M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -9.54M | -1.16M | 164.00K | -3.69 | -1.91 | -1.70 | 0.00 | -0.39 |
| Net Income | -95.73M | -47.26M | -93.04M | -34.10M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| EPS Diluted | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| Weighted Avg Shares Out | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
| Weighted Avg Shares Out (Dil) | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been...
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and...
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of...
Mind Medicine: No News = Good News
Mind Medicine's share price has responded very strongly to a third quarter update that contained very little new information. The market appears to have moved to a bullish stance following confirmation that clinical timelines have not been changed. With a...
Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephanie Fagan – Chief Corporate Affairs Officer Rob Barrow – Chief Executive Officer Dan Karlin – Chief Medical Officer Conference Call...
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the...
Psychedelic Stocks: Focus On Their Cash
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine...
MindMed readying Phase III trials for LSD therapy to treat anxiety
MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a...
Pacific Defense Announces US Army CMFF Program Team
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team...
Source: https://incomestatements.info
Category: Stock Reports